ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Centre Léon Bérard at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Centre Léon Bérard takes part in 20 sessions at ESMO 2026 in Madrid. Its program spans emerging treatments and precision approaches in lung, gynaecological and rare cancers. Topics include genomic testing to diagnose complex sarcomas and registry data on uterine sarcoma characteristics and outcomes.
| Organization | ESMO 2026 Attendance |
|---|---|
Centre Léon Bérard Lyon, France | |
Comprehensive cancer centre in Lyon, France, part of the Unicancer network of French cancer centres. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Chair Fri Oct 23 16:15–17:45 Beyond traditional therapy: The impact of emerging approaches on sarcoma treatment Sarcoma, CNS, head & neck and rare cancers Chair Sat Oct 24 10:15–11:45 Talk Sat Oct 24 11:05–11:20 Systemic therapies: From localised to metastatic disease Sarcoma, CNS, head & neck and rare cancers Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Satellite Sat Oct 24 13:15–13:20 Audience polling Gynaecological cancers Satellite Sat Oct 24 13:55–14:10 Spotlight on PROC: An In-Depth Exploration of ADCs in Development Gynaecological cancers Chair Sun Oct 25 08:30–09:15 Locally advanced vulvar cancer Gynaecological cancers Chair Sun Oct 25 08:30–10:00 Rapid oral 2: NSCLC, metastatic Lung & thoracic cancers Abstract Sun Oct 25 09:02–09:14 Invited Discussant 2661RO and 2617RO Lung & thoracic cancers Chair Sun Oct 25 10:15–11:45 Abstract Sun Oct 25 10:25–10:35 Abstract Sun Oct 25 10:35–10:45 Poster Sun Oct 25 12:00–12:45 Abstract Mon Oct 26 09:07–09:12 3722RO - Trastuzumab deruxtecan in patients with desmoplastic small round cell tumors (DSRCT): A retrospective analysis from the French Sarcoma Group Sarcoma, CNS, head & neck and rare cancers Abstract Mon Oct 26 09:24–09:29 3723RO - Desmoid tumors (DTs) from the NETSARC+ registry: Tumor characteristics, management strategies, and outcomes in 3457 patients Sarcoma, CNS, head & neck and rare cancers Chair Mon Oct 26 10:15–11:30 Optimal management of high-grade serous ovarian cancer with BRCA mutation Gynaecological cancers Talk Mon Oct 26 10:45–11:00 Drug interventions to reduce the risk of second primaries: Where do we stand? Nursing & supportive care Abstract Mon Oct 26 11:12–11:17 Poster Mon Oct 26 12:00–12:45 Added value of systematic sequencing in diagnostic of complex genomic sarcoma: Results of the prospective RNASarc study Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 Genomic landscape of head and neck squamous cell carcinoma in a prospective molecular screening program: The PROFILER experience Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Uterine sarcomas: Heterogeneity of presentation and outcome for the 3,110 patients from the NETSARC+ registry Gynaecological cancersSarcoma, CNS, head & neck and rare cancers |
Find decision makers at Centre Léon Bérard
Tell us what you sell and we’ll find the people at Centre Léon Bérard most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction